P-glycoprotein: a defense mechanism limiting oral bioavailability and CNS accumulation of drugs
- PMID: 10706193
- DOI: 10.5414/cpp38069
P-glycoprotein: a defense mechanism limiting oral bioavailability and CNS accumulation of drugs
Abstract
Transport by ATP-dependent efflux pumps such as P-glycoprotein is an increasingly recognized determinant of drug disposition. P-glycoprotein does not only contribute to multidrug resistance (MDR) in tumor cells, it is also expressed in normal tissues with excretory function such as liver, kidney and intestine. Apical expression of P-glycoprotein in such tissues results in reduced drug absorption from the gastrointestinal tract and enhanced drug elimination into bile and urine. Moreover, expression of P-glycoprotein in the endothelial cells of the blood-brain barrier prevents entry of certain drugs into the central nervous system. Human P-glycoprotein has been shown to transport a wide range of structurally unrelated drugs such as digoxin, quinidine, cyclosporine and HIV-1 protease inhibitors. Drug administration to P-glycoprotein knock-out and control mice provided data on the importance of P-glycoprotein for absorption after oral administration and penetration through the blood-brain barrier. Moreover, P-glycoprotein knock-out mice were used to identify inhibition of P-glycoprotein-mediated transport as a mechanism for drug interactions such as the digoxin-quinidine interaction. Studies in humans indicate a particular importance of intestinal P-glycoprotein for bioavailability of the immunosuppressant cyclosporine. Moreover, induction of intestinal P-glycoprotein by rifampin has now been identified as the major underlying mechanism of reduced digoxin plasma concentrations during concomitant rifampin therapy. In summary, P-glycoprotein functions as a defense mechanism, which determines bioavailability and CNS concentrations of drugs. Modification of P-glycoprotein function is an important underlying mechanism of drug interactions in humans. However, disposition of a drug and its metabolites frequently is not only determined by P-glycoprotein, but also by drug-metabolizing enzymes and possibly by drug transporters other than P-glycoprotein [e.g. members of the MRP family (MRP = multidrug resistance-associated proteins)].
Similar articles
-
Importance of P-glycoprotein for drug disposition in humans.Eur J Clin Invest. 2003 Nov;33 Suppl 2:6-9. doi: 10.1046/j.1365-2362.33.s2.4.x. Eur J Clin Invest. 2003. PMID: 14641550 Review.
-
Role of P-glycoprotein in drug disposition.Ther Drug Monit. 2000 Feb;22(1):137-40. doi: 10.1097/00007691-200002000-00029. Ther Drug Monit. 2000. PMID: 10688277 Review.
-
The role of the transporter P-glycoprotein for disposition and effects of centrally acting drugs and for the pathogenesis of CNS diseases.Eur Arch Psychiatry Clin Neurosci. 2006 Aug;256(5):281-6. doi: 10.1007/s00406-006-0662-6. Eur Arch Psychiatry Clin Neurosci. 2006. PMID: 16783494 Review.
-
Inhibition of P-glycoprotein-mediated drug transport: A unifying mechanism to explain the interaction between digoxin and quinidine [seecomments].Circulation. 1999 Feb 2;99(4):552-7. doi: 10.1161/01.cir.99.4.552. Circulation. 1999. PMID: 9927403
-
Kinetic and biochemical analysis of carrier-mediated efflux of drugs through the blood-brain and blood-cerebrospinal fluid barriers: importance in the drug delivery to the brain.J Control Release. 1999 Nov 1;62(1-2):179-86. doi: 10.1016/s0168-3659(99)00036-x. J Control Release. 1999. PMID: 10518649 Review.
Cited by
-
Nanomedicine in the diagnosis and therapy of neurodegenerative disorders.Prog Polym Sci. 2007;32(8-9):1054-1082. doi: 10.1016/j.progpolymsci.2007.05.014. Prog Polym Sci. 2007. PMID: 20234846 Free PMC article.
-
Vanadate trapping of nucleotide at the ATP-binding sites of human multidrug resistance P-glycoprotein exposes different residues to the drug-binding site.Proc Natl Acad Sci U S A. 2002 Mar 19;99(6):3511-6. doi: 10.1073/pnas.022049799. Epub 2002 Mar 12. Proc Natl Acad Sci U S A. 2002. PMID: 11891276 Free PMC article.
-
MDR1 gene polymorphisms and disposition of the P-glycoprotein substrate fexofenadine.Br J Clin Pharmacol. 2002 May;53(5):526-34. doi: 10.1046/j.1365-2125.2002.01591.x. Br J Clin Pharmacol. 2002. PMID: 11994059 Free PMC article. Clinical Trial.
-
High frequency of a single nucleotide substitution (c.-6-180T>G) of the canine MDR1/ABCB1 gene associated with phenobarbital-resistant idiopathic epilepsy in Border Collie dogs.Dis Markers. 2013;35(6):669-72. doi: 10.1155/2013/695918. Epub 2013 Nov 5. Dis Markers. 2013. PMID: 24302812 Free PMC article.
-
The Toxic Effects of Polychemotherapy onto the Liver Are Accelerated by the Upregulated MDR of Lymphosarcoma.ISRN Oncol. 2012;2012:721612. doi: 10.5402/2012/721612. Epub 2012 Nov 29. ISRN Oncol. 2012. PMID: 23251817 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Medical